Meeting
2022 ASCO Annual Meeting
Evaluation of weight gain and overall survival of patients with advanced non–small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy.
Authors
Eric Roeland
Oregon Health and Sciences University Knight Cancer Institute, Portland, OR
Eric Roeland , Florian J. Fintelmann , Fiona Hilton , Lisa Tarasenko , Roberto A Calle , Philip D. Bonomi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT00254891, NCT00254904, and NCT00596830
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9088)
DOI
10.1200/JCO.2022.40.16_suppl.9088
Abstract #
9088
Poster Bd #
75
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Quality Care Symposium
Comparative effectiveness of first-line chemotherapies in advanced non-small cell lung cancer.
First Author: Jennifer T. Chang
Poster
2011 ASCO Annual Meeting
Drug pathway-associated gene polymorphisms in patients with advanced non-small cell lung cancer receiving first-line platinum-gemcitabine combination chemotherapy: A prospective multicenter observational study.
First Author: M. Joerger
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu